Last reviewed · How we verify

Talazoparib with enzalutamide (talazoparib-with-enzalutamide)

Pfizer · FDA-approved active Quality 50/100

Talazoparib with enzalutamide (generic name: talazoparib-with-enzalutamide) is a PARP inhibitor and androgen receptor inhibitor drug developed by Pfizer. It is currently FDA-approved (first approved Not ) for Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations.

Talazoparib in combination with enzalutamide is an investigational therapy being developed by Pfizer Inc. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The combination leverages the PARP inhibition properties of talazoparib and the androgen receptor signaling inhibitor properties of enzalutamide to enhance antitumor activity. While there is no FDA-approved label for this combination, clinical trials have shown promising results in extending progression-free survival and improving overall outcomes in patients with mCRPC. However, the combination therapy also comes with a range of side effects that need to be managed carefully. Pfizer is actively pursuing regulatory approval for this combination, and it has the potential to become a significant addition to the treatment landscape for mCRPC.

At a glance

Generic nametalazoparib-with-enzalutamide
SponsorPfizer
Drug classPARP inhibitor and androgen receptor inhibitor
TargetPARP enzymes and androgen receptor
Therapeutic areaOncology
PhaseFDA-approved
First approvalNot yet launched
Annual revenue2194

Approved indications

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Talazoparib with enzalutamide

What is Talazoparib with enzalutamide?

Talazoparib with enzalutamide (talazoparib-with-enzalutamide) is a PARP inhibitor and androgen receptor inhibitor drug developed by Pfizer, indicated for Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations.

What is Talazoparib with enzalutamide used for?

Talazoparib with enzalutamide is indicated for Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations.

Who makes Talazoparib with enzalutamide?

Talazoparib with enzalutamide is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Talazoparib with enzalutamide?

talazoparib-with-enzalutamide is the generic (nonproprietary) name of Talazoparib with enzalutamide.

What drug class is Talazoparib with enzalutamide in?

Talazoparib with enzalutamide belongs to the PARP inhibitor and androgen receptor inhibitor class. See all PARP inhibitor and androgen receptor inhibitor drugs at /class/parp-inhibitor-and-androgen-receptor-inhibitor.

When was Talazoparib with enzalutamide approved?

Talazoparib with enzalutamide was first approved on Not yet launched.

What development phase is Talazoparib with enzalutamide in?

Talazoparib with enzalutamide is FDA-approved (marketed).

What is Talazoparib with enzalutamide's annual revenue?

Talazoparib with enzalutamide generated approximately $0.0B in annual revenue.

What does Talazoparib with enzalutamide target?

Talazoparib with enzalutamide targets PARP enzymes and androgen receptor and is a PARP inhibitor and androgen receptor inhibitor.

Related